Ghrelin may inhibit myostatin activation by inactivating p38 and C/EBPβ and act directly on myoblasts to prevent cisplatin‐induced myasthenia in the absence of GHSR1a,91 suggesting the possibility that ghrelin may play a role in preventing myasthenia gravis or sarcopenia. The gene discussed is GHRL; the disease is Fatigable weakness.